Recursion Announces Positive Phase 2 Data for REC-4881 in TUPELO Trial

Recursion Pharmaceuticals reported positive Phase 2 TUPELO trial data for REC-4881, an oral MEK1/2 inhibitor being studied for familial adenomatous polyposis. In the expanded adult population, 47% of patients achieved a median reduction in total polyp burden after 12 weeks, with deep and durable reductions reported across the gastrointestinal tract. Recursion plans to begin a registrational trial in the second half of 2027, subject to further discussions with the FDA.